(Q36550468)

14 August 2017

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia (English)

1 reference

14 August 2017

0 references

1 reference

Lorenzo De Paoli

3

0 references

Gian Matteo Rigolin

Gian Matteo Rigolin

20

0 references

Roberto Marasca

Roberto Marasca

23

0 references

Francesco Forconi

Francesco Forconi

13

0 references

Massimo Massaia

Massimo Massaia

27

0 references

Francesca Romana Mauro

Francesca R Mauro

9

0 references

Pier Luigi Zinzani

28

Pier Luigi Zinzani

1 reference

14 August 2017

Francesco Zaja

12

0 references

Marta Coscia

Marta Coscia

19

0 references

Omar Perbellini

Omar Perbellini

24

0 references

Valter Gattei

Valter Gattei

31

0 references

Agostino Cortelezzi

Agostino Cortelezzi

11

0 references

Antonino Neri

Antonino Neri

22

0 references

Robin Foà

32

Robin Foà

1 reference

14 August 2017

33

Gianluca Gaidano

1 reference

Lodovico Terzi-di-Bergamo

14 August 2017

2

Lodovico Terzi-di-Bergamo

1 reference

14 August 2017

7

Pietro Bulian

1 reference

14 August 2017

15

Ilaria Del Giudice

1 reference

14 August 2017

21

Alessandra Tedeschi

1 reference

14 August 2017

29

Marco Montillo

1 reference

14 August 2017

30

Antonio Cuneo

1 reference

14 August 2017

6

Annalisa Chiarenza

1 reference

14 August 2017

4

Michaela Cerri

1 reference

14 August 2017

10

Fortunato Morabito

1 reference

14 August 2017

16

Massimo Gentile

1 reference

14 August 2017

17

Iolanda Vincelli

1 reference

14 August 2017

Davide Rossi

1

1 reference

14 August 2017

Guido Ghilardi

5

1 reference

14 August 2017

Carlo Visco

8

1 reference

14 August 2017

Luca Laurenti

14

1 reference

14 August 2017

Marina Motta

18

1 reference

14 August 2017

Carol Moreno

25

1 reference

14 August 2017

Giovanni Del Poeta

26

1 reference

14 August 2017

language of work or name

English

0 references

publication date

14 August 2015

1 reference

14 August 2017

1 reference

14 August 2017

126

1 reference

14 August 2017

16

1 reference

14 August 2017

1921-1924

1 reference

Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

A mechanism-driven treatment for chronic lymphocytic leukemia?

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4743433

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26276669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Changes in the treatment landscape for chronic lymphoid leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26276669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Solid tumors after chronic lymphocytic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26276669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2015-05-647925

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

26276669

1 reference